Provider review
Trava Health Review: FDA Does Not Approve Laboratories
Trava Health's headline assurance is that its GLP-1s are “tested in FDA approved labs”. FDA does not approve laboratories — it approves drugs — and the phrase is the only mention of testing anywhere on the site. No certificate of analysis, potency result or third-party report is published to stand behind it.
Correction, August 2026
This review previously said: “$118 is a quarterly package divided, not a monthly rate — the site shows “$117.96 / monthly” and “Save $87.92 with Our Quarterly Package”, and the cents are the giveaway.”
That was wrong. The cents were read as evidence of a divided package total. They are not evidence of anything on their own, and the arithmetic that would have settled it was never done: three monthly payments minus the stated quarterly saving, divided by three, gives a different and lower figure — the one Trava prints on its own home page card. A number's shape is not a source. Doing the division would have taken one line.
It now says: The advertised figure is the monthly rate, printed as "/ monthly" on the product page. The quarterly package is the cheaper option, and its effective monthly rate is the lower figure on the home page card. What is genuinely inconsistent is the banner, which advertises GLP-1s "as low as" the monthly rate rounded up — above the lowest price on the card beneath it — and the fact that the semaglutide and tirzepatide cards use "As Low As" to mean the quarterly rate and the monthly rate respectively.
Sells on a testing guarantee that names a regulator which does not do that, and publishes no test result of any kind.
Worth trusting if
- You have obtained a certificate of analysis directly and independently of the site
- You are buying the quarterly package and have compared the package total rather than the monthly figure
Be skeptical if
- You are relying on “tested in FDA approved labs” as a quality assurance
- You want the compounding pharmacy or laboratory named
- You want any published test result at all
Compounded only
Phase 3 trials
Not named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens taketrava.com. A link is not a recommendation to take anything.
Provenance
What Trava Health actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded Semaglutide — Re-read 2026-08-26, and the 2026-08-14 note had this the wrong way round — see the correction on this page. $117.96 is the monthly rate, printed as such on the semaglutide page. The quarterly package takes $87.92 off three of those months, which works out at $88.65 a month, and that figure is what Trava's own home page card advertises for semaglutide. Meanwhile the banner across every page reads “GLP-1’s As Low as $118”, which is the monthly rate rounded up — higher than the lowest price on its own card. Tirzepatide is $178.98 a month, with $94.96 off a quarter, so about $147.33 a month on the package. Its card advertises the monthly figure as "As Low As", while the semaglutide card advertises the quarterly one, so the same two words mean different things in the same row.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
1
Molecules with human evidence
For the use they are sold for, out of 1 products reviewed here. The evidence belongs to the molecule, not to Trava Health.
1
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Trava Health’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Compounded SemaglutideSemaglutide · Compounded (503A)No trial supports this claim
“GLP-1's As Low as $118 tested in FDA approved labs”
Read on the Trava Health site, August 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Semaglutide 2.4 mg over 68 weeks — the trial record for the FDA-approved product. It says nothing about how any compounded preparation was made or tested.
As of 2026-08-14 a read of its own site returned no certificate of analysis, no potency or purity result, no third-party report and no named laboratory. The phrase “tested in FDA approved labs” is the only reference to testing on the site, and nothing is published behind it.
Graded unsupported because the claim describes a regulatory status that does not exist. FDA approves drugs and clears devices; it does not approve, license, certify or accredit laboratories. Clinical laboratories operate under CLIA and state regulation, and compounded drugs are not FDA-approved at all. Where the phrase sits makes it worse. It is attached to the word “tested”, which is the one assurance a compounded-drug buyer is actually after, and it is the only mention of testing on the site. Nothing is published behind it — no certificate, no result, no laboratory named.1
Dispensing chain
Who actually fills your prescription
Read the full account
No pharmacy is named, and no regulatory category — 503A or 503B — is stated anywhere on the public pages. Re-checked 2026-08-26: there is now a supply-chain statement, and it is a correct one, in the footer. It says Trava “works with state-licensed pharmacies that compound and dispense products consistent with state and federal law and applicable safety and sterility standards set by the United States Pharmacopoeia”, and that compounded medications “are not FDA approved and have not been evaluated for safety and effectiveness by the FDA”. State boards and USP are the right authorities. No facility is named, and the banner in the largest type on the same page still says the medication is tested in FDA approved labs.
Read on the Trava Health site, August 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
Testing is the site's headline assurance and nothing supports it. No certificate of analysis, potency result, purity result or third-party report is published or offered, and no laboratory or pharmacy is named that could supply one. The claim itself — “FDA approved labs” — refers to an approval FDA does not issue.
Read on the Trava Health site, August 2026.
Licensing
Licensed to dispense, and where
Coverage
No state list or set of exclusions is published on the public pages, re-checked 2026-08-26.
Read the full licensing claim
Prescribing is through a named partner group, Wasef Health Physicians, with six physicians named individually and each given their own page: Dr. Michael Wasef, MD (founder, internal medicine), Dr. David Wasef, MD, Dr. Andrew Sakla, DO, Dr. Asad Khan Niazi, MD, Dr. James Teet, DO, and Dr. Constantin Chikando, MD. Naming them is what makes them checkable. The site's headline claim about its supply chain remains "tested in FDA approved labs", which describes an approval FDA does not issue.
Read on the Trava Health site, August 2026.
Regulatory
The FDA warning letter
Checked, and none found
We did this ourselves
What happens when you sign up with Trava Health
We went through Trava Health’s signup ourselves in August 2026 to find out what you actually meet before you pay — the steps, when a price appears, and what it asks for. We used placeholder answers, and we stopped before paying, so nothing here is a prescription or a medical outcome. It is what the screens showed.
- Press "Take The Free Quiz" or "Start your consult". Every product price is already public.
- Say what you are hoping to achieve, from five options, choosing as many as apply.
- Enter an email address.
- "Create an account" — first name, last name and a password of at least eight characters with an uppercase letter, a number and a symbol, plus a terms and telehealth consent box.
- This walk stopped there. We do not create password-protected accounts, so nothing past that screen was seen.
- Both GLP-1s are priced before any question. Semaglutide is $117.96 a month, or $88.65 a month on the quarterly package. Tirzepatide is $178.98 a month, or about $147.33 on the quarterly.
- The banner on every page advertises GLP-1s "as low as" a figure higher than the lowest one on its own semaglutide card.
- The dose menus are published on the product pages: semaglutide 0.25 to 2.5 mg, tirzepatide 2.5 to 15 mg, with no price change stated between rungs.
- The page called "Our Transparent Pricing" sets a monthly plan against a quarterly one — "Save up to 33%" — and prints no figure for either.
- The banner says the medication is "tested in FDA approved labs". The footer on the same page says compounded medications "are not FDA approved" and that Trava works with "state-licensed pharmacies". The footer is right.
- Six physicians are named with individual pages, under a named partner group, Wasef Health Physicians.
- The visit demands a password-protected account at the third screen, before a single medical question.
Trava Health support
- Phone
- 1-855-872-8279
Assessment
What holds up, and what does not
- The effective price is toward the cheap end of the compounded semaglutide market.
- The quarterly package's saving is stated in dollars against the monthly figure, so the two are directly comparable.
- Both semaglutide and tirzepatide are priced on public pages rather than behind an intake, and the monthly rate is printed as a monthly rate.
Show 2 more
- It names its clinical partner group and six individual physicians, each with their own page — Wasef Health Physicians, led by Dr. Michael Wasef, MD.
- Its footer disclosure is correct where the banner is not: compounded medications "are not FDA approved and have not been evaluated for safety and effectiveness by the FDA", and Trava "works with state-licensed pharmacies" meeting United States Pharmacopoeia standards.
- “Tested in FDA approved labs” describes a regulatory category that does not exist. FDA approves drugs and clears devices; it does not approve, license or accredit laboratories.
- Testing is the headline assurance and nothing is published behind it — no certificate of analysis, no potency or purity result, no third-party report.
- No laboratory is named, so the claim cannot be traced to any facility.
Show 7 more
- No compounding pharmacy is named and no regulatory category is stated.
- The banner's "as low as" GLP-1 figure is higher than the lowest price on its own semaglutide card.
- The two GLP-1 cards use "As Low As" to mean different things: the quarterly effective rate on one, the monthly rate on the other.
- The page headed "Our Transparent Pricing" describes a monthly and a quarterly plan and carries no figure for either.
- The site's own footer contradicts its own banner on what FDA does, and the banner is the sentence in the largest type.
- No state coverage list or exclusions are published.
- The visit demands a password-protected account at its third screen, before any medical question.
Verdict
The bottom line
The one thing Trava asks you to trust it on — testing — is described using an approval that does not exist and backed by nothing published. If testing is why you are considering this company, that is the reason not to, unless you obtain a certificate of analysis directly first.
Opens taketrava.com. A link is not a recommendation to take anything.
The claim
“GLP-1’s As Low as $118 tested in FDA approved labs”
Full analysis — 7 more sectionsWhy it is wrong · Why this one is worse than the others · What is published behind it · The trials, and what they cover · What it costs, and where the banner goes wrong · The footer already knows · What this means if you are buying
Why it is wrong
There is no such thing as an FDA-approved laboratory.
FDA approves drugs and clears devices. Clinical laboratories in the United States are regulated under CLIA — the Clinical Laboratory Improvement Amendments — and by state authorities. Compounding pharmacies are licensed by state boards of pharmacy. FDA neither approves nor licenses nor accredits any of them.
And compounded drugs are not FDA-approved either, which is the further problem: the phrase attaches FDA's name to a product category FDA has specifically not reviewed.
Why this one is worse than the others
Three companies in this batch invented an FDA category. GOAL.MD claims "FDA-monitored 503A/B pharmacies". OrderlyMeds was cited by FDA itself for saying "FDA-licensed pharmacy". Trava says "FDA approved labs".
The difference is what the phrase is doing. The others describe who makes the drug. This one describes testing — and testing is the specific assurance a person buying a compounded injectable is trying to obtain, because it is the thing that separates a properly made preparation from an improperly made one.
It is also the only mention of testing anywhere on the site.
What is published behind it
Nothing.
No certificate of analysis. No potency result. No purity result. No third-party report. No named laboratory. No named pharmacy. No regulatory category.
The assurance is the entire content of the assurance.
The trials, and what they cover
Semaglutide has substantial phase 3 weight-loss evidence. 1 Tirzepatide does too. 2
Those trials tested FDA-approved finished products made to registered specifications under manufacturing oversight. They establish what the molecule does when it is properly made. They say nothing about how any particular compounded preparation was made, what is in the vial, or whether it was tested — which is exactly the gap a testing claim is supposed to fill.
What it costs, and where the banner goes wrong
Everything is priced in public, which is worth saying first — no intake, no email wall. Re-read on 26 August 2026:
- Semaglutide — $117.96 a month, or $87.92 off a quarter, which is $88.65 a month on the package
- Tirzepatide — $178.98 a month, or $94.96 off a quarter, about $147.33 a month on the package
An earlier version of this review said the advertised figure was a quarterly total divided. It is not; it is the monthly rate, and the correction is at the top of this page.
What is genuinely inconsistent is the banner. It runs across every page reading "GLP-1's As Low as" the monthly figure rounded up — and the semaglutide card on the home page beneath it advertises a lower number, the quarterly effective rate. A headline "as low as" that is higher than the price on the card under it is not a rounding question.
The two GLP-1 cards also disagree with each other about what "As Low As" means. On semaglutide it is the quarterly rate. On tirzepatide it is the monthly one. Same two words, same row of cards, two different quantities.
And the page titled "Our Transparent Pricing" describes a monthly plan and a quarterly plan, promises "Save up to 33%", and prints no number for either.
The footer already knows
One more thing found on the re-read, and it is the site correcting itself in small type:
"Compounded medications are available by prescription only. They are not FDA approved and have not been evaluated for safety and effectiveness by the FDA. Trava works with state-licensed pharmacies that compound and dispense products consistent with state and federal law and applicable safety and sterility standards set by the United States Pharmacopoeia."
That is right. State boards license compounding pharmacies; USP sets the sterility standards; compounded drugs are not FDA-approved. It sits at the bottom of the same page whose banner says the medication is tested in FDA approved labs. A company that can write the accurate sentence has no excuse for the banner.
What this means if you are buying
Ask for the certificate of analysis for your lot before you pay, and ask which pharmacy compounded it. If those are not forthcoming, the testing claim on the homepage should be treated as marketing copy rather than as information. On price, work out the quarterly package's per-month figure yourself rather than reading the banner.
Questions
Frequently asked questions
What is an FDA-approved lab?
Nothing — there is no such category. FDA approves drugs and clears medical devices. Clinical laboratories are regulated under CLIA and by state authorities, and compounding pharmacies are licensed by state boards of pharmacy. Compounded drugs are not FDA-approved either.
Does Trava publish any test results?
No. Despite testing being its headline claim, no certificate of analysis, potency result, purity result or third-party report appears anywhere on the site, and no laboratory or pharmacy is named who could provide one.
Is $117.96 the monthly price?
Yes, and this review previously said otherwise — the correction is at the top of the page. Re-read on 26 August 2026, the semaglutide page prints its monthly figure as the monthly rate, and the quarterly package is the cheaper option: it takes a fixed amount off three of those months, which works out lower per month and is the number Trava's own home page card advertises for semaglutide. What is worth watching is the banner. It quotes a GLP-1 figure “as low as” a number that is higher than the lowest price on the card underneath it, and the tirzepatide card uses the same two words to mean the monthly rate while the semaglutide card uses them to mean the quarterly one.
Compare
Others selling what Trava Health sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Trava Health's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 2 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.